Beglis Tablet (Booglybose)

Adult dose

Since efficacy and tolerability vary between patients, the physician must determine the dose based on the patient's condition. The usual dosage is as follows. Adults are generally administered voglibose 0.2mg per dose orally 3 times daily before each meal. If the effect is inadequate, the dose per administration may be increased to 0.3mg while closely monitoring the patient's progress.

This medication should not be administered to patients with severe ketoacidosis, diabetic coma, or pre-coma. In these cases, intravenous fluids and insulin therapy are necessary. This medication should also not be given to patients with severe infections, pre- or post-operative conditions, or severe trauma; in these instances, insulin therapy is recommended. Patients who have had allergic reactions to this medication's ingredients should not use it. This medication should be used cautiously in chronic intestinal disease patients with digestive and absorption disorders, as the patient's condition may worsen. Caution is also required when using this medication in patients with increased intestinal gas that could worsen their symptoms, such as those with a history of abdominal surgery or bowel obstruction. Patients with severely impaired liver or kidney function should be aware that changes in metabolism may alter blood sugar control. Elderly patients may have decreased physiological functions, so treatment should start at a low dose and blood sugar and gastrointestinal symptoms should be monitored. When used in conjunction with other hypoglycemic agents, there is a risk of hypoglycemia; treatment should begin with a low dose, and patients should be adequately informed of the symptoms of hypoglycemia. During treatment, blood sugar should be checked regularly, and if blood sugar control remains insufficient after 2-3 months of administration, treatment options should be reassessed. As this medication inhibits the breakdown of sugar (sucrose), if hypoglycemic symptoms occur, glucose should be administered instead of sugar. In cases of severe hypoglycemia, intravenous glucose infusion or glucagon injection may be necessary. Patients with severe liver dysfunction may experience symptoms such as hepatitis or jaundice and should immediately stop the medication if such symptoms occur. The safety of this medication during pregnancy or in women of childbearing potential has not been established; it should only be administered if the benefits outweigh the risks. Breastfeeding women are advised to avoid this medication, and if it is absolutely necessary to administer it, breastfeeding should be discontinued. Safety in pediatric patients has not been confirmed, so its use is not recommended.

• Hypoglycemia
• abdominal distension
• increased flatulence
• symptoms of intestinal obstruction
• acute hepatitis
• elevated AST
• elevated ALT
• severe liver dysfunction
• jaundice
• exacerbation of hyperammonemia

This medication may be sensitive to air and moisture, so it should be stored in a sealed container. Additionally, it is advisable to store the medication at room temperature, which should not be too hot or cold, between 1 to 30 degrees Celsius. Storing it this way helps maintain the medication's effectiveness for safe use.

Appearance

White to yellowish-white round tablet

Package unit

300 tablets/bottle, 90 tablets (10 tablets/PTP × 9)